Stapled Peptide Cancer Vaccine Achieves 100% Tumor Prevention for 11 Months in Mice
A sulfonium-stapled peptide nano-vaccine achieved 100% tumor prevention for 11 months and eliminated established colon tumors in 40% of mice by dramatically improving neoantigen delivery and T cell activation.
Quick Facts
What This Study Found
100% tumor prevention for 11 months without recurrence in the prevention model; 40% complete tumor elimination in established MC-38 colon tumors; potent CTL infiltration into tumor microenvironment; efficient antigen/adjuvant co-delivery to draining lymph nodes.
Key Numbers
Nano-vaccine stimulated strong tumor-specific T cell responses through enhanced antigen uptake and cross-presentation pathways.
How They Did This
Developed sulfonium-stapled peptide-nucleic acid conjugate self-assembling nanoparticles. Tested in prophylactic (tumor prevention) and therapeutic (established tumor) models using MC-38 colon cancer. Assessed lymph node delivery, antigen presentation, TLR signaling, T cell responses, and systemic toxicity.
Why This Research Matters
Neoantigen vaccines could potentially cure cancer by training each patient's immune system against their specific tumor. The stapled peptide approach solves the critical delivery problem that has held back neoantigen vaccines in clinical trials.
The Bigger Picture
Published in Advanced Science, this study addresses the biggest limitation of personalized cancer vaccines — getting neoantigen peptides into immune cells efficiently. By using stapled peptides that self-assemble with adjuvants, the vaccine achieves the antigen presentation and T cell activation that natural peptide antigens cannot. The 100% prevention and 40% cure rates are among the best reported for any neoantigen vaccine in preclinical models.
What This Study Doesn't Tell Us
Mouse study — human immune responses are more complex. The MC-38 tumor model is moderately immunogenic, which may favor vaccine approaches. Manufacturing personalized stapled peptide neoparticles for each patient is complex. Only single neoantigen tested in therapeutic model — multi-neoantigen approaches may be needed.
Questions This Raises
- ?Can this platform be manufactured at scale for personalized patient treatment?
- ?Would multi-neoantigen stapled peptide vaccines improve the 40% cure rate in established tumors?
- ?How will this approach perform against less immunogenic or immune-cold tumors?
Trust & Context
- Key Stat:
- 100% prevention, 11 months Stapled peptide nano-vaccine prevented all tumors for nearly a year with long-term immune memory and no recurrence
- Evidence Grade:
- Moderate evidence: published in Advanced Science with impressive preclinical results in both prevention and treatment models, but no human data yet.
- Study Age:
- Published in 2024 in Advanced Science. Among the most promising preclinical cancer vaccine results reported.
- Original Title:
- Sulfonium-Stapled Peptides-Based Neoantigen Delivery System for Personalized Tumor Immunotherapy and Prevention.
- Published In:
- Advanced science (Weinheim, Baden-Wurttemberg, Germany), 11(24), e2307754 (2024)
- Authors:
- Zhang, Yaping(3), Jiang, Leying(2), Huang, Siyong, Lian, Chenshan, Liang, Huiting, Xing, Yun, Liu, Jianbo, Tian, Xiaojing, Liu, Zhihong, Wang, Rui, An, Yuhao, Lu, Fei, Pan, Youdong, Han, Wei, Li, Zigang, Yin, Feng
- Database ID:
- RPEP-09659
Evidence Hierarchy
Frequently Asked Questions
What is a stapled peptide vaccine?
Stapled peptides are chemically reinforced with molecular "staples" that improve their stability and ability to interact with immune cells. In this vaccine, the stapled neoantigen peptides self-assemble with immune-boosting adjuvants into nanoparticles that efficiently deliver cancer-specific signals to the immune system.
Could this approach cure cancer in humans?
The mouse results are among the most impressive for any neoantigen vaccine, but human cancer is more complex. Clinical trials will need to demonstrate safety, determine optimal neoantigen selection, and confirm immune activation in patients. If successful, it could become a powerful tool for personalized cancer treatment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09659APA
Zhang, Yaping; Jiang, Leying; Huang, Siyong; Lian, Chenshan; Liang, Huiting; Xing, Yun; Liu, Jianbo; Tian, Xiaojing; Liu, Zhihong; Wang, Rui; An, Yuhao; Lu, Fei; Pan, Youdong; Han, Wei; Li, Zigang; Yin, Feng. (2024). Sulfonium-Stapled Peptides-Based Neoantigen Delivery System for Personalized Tumor Immunotherapy and Prevention.. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 11(24), e2307754. https://doi.org/10.1002/advs.202307754
MLA
Zhang, Yaping, et al. "Sulfonium-Stapled Peptides-Based Neoantigen Delivery System for Personalized Tumor Immunotherapy and Prevention.." Advanced science (Weinheim, 2024. https://doi.org/10.1002/advs.202307754
RethinkPeptides
RethinkPeptides Research Database. "Sulfonium-Stapled Peptides-Based Neoantigen Delivery System ..." RPEP-09659. Retrieved from https://rethinkpeptides.com/research/zhang-2024-sulfoniumstapled-peptidesbased-neoantigen-delivery
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.